Intra-Cellular Therapies Inc CEO Sharon Mates Sells 191,362 Shares
Sharon Mates, the Chairman, President & CEO of Intra-Cellular Therapies Inc (NASDAQ:ITCI), has sold 191,362 shares of the company on January 18, 2024, according to a recent SEC Filing. The transaction was executed at an average price of $66.27 per share, resulting in a total value of $12,678,493.74.
Intra-Cellular Therapies Inc is a biopharmaceutical company focused on the discovery and development of drugs for the treatment of neuropsychiatric and neurological disorders. The company is dedicated to creating innovative treatments to improve the lives of patients.
Over the past year, the insider has sold a total of 404,135 shares of Intra-Cellular Therapies Inc and has not made any purchases of the stock. The recent sale by the insider is part of a trend observed over the last year, where there have been no insider buys but 28 insider sells.
On the date of the insider's recent sale, shares of Intra-Cellular Therapies Inc were trading at $66.27, giving the company a market capitalization of $6.269 billion.
The stock's price-to-GF-Value ratio stands at 0.29, with a GuruFocus Value of $229.92, indicating that the stock is considered a Possible Value Trap, Think Twice based on its GF Value. The GF Value is a proprietary intrinsic value estimate from GuruFocus, which factors in historical trading multiples, a GuruFocus adjustment factor based on the company's past performance, and future business performance estimates from Morningstar analysts.
The insider transaction history and the GF Value are important indicators for investors considering the stock's valuation and insider sentiment.
Investors and analysts often monitor insider transactions as they can provide insights into the insider's perspective on the value and prospects of the company.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
